Streetbeat News

TSBX

Turnstone Biologics Corp.

Industry

Biotechnology

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Open

0.48

Mkt cap

11M

Volume

42K

High

0.50

P/E Ratio

-0.22

52-wk high

5.75

Low

0.46

Div yield

N/A

52-wk low

0.40

B of A Securities has downgraded Turnstone Biologics from Buy to Neutral and significantly lowered its price target from $10 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:43 am

Turnstone Biologics is streamlining operations to extend its cash runway into Q2 2026 by focusing on the clinical advancement of its TIDAL-01 therapy. The company is reallocating resources from other preclinical assets and has made leadership changes to support this focus.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 10:06 am

Turnstone Biologics is planning a major restructuring by reducing its workforce by approximately 60%. This move is likely aimed at cutting costs and refocusing the company's resources.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 10:00 am

B of A Securities has maintained a Buy rating on Turnstone Biologics (NASDAQ:TSBX) but has lowered the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 4:46 pm

Piper Sandler has maintained an Overweight rating on Turnstone Biologics but significantly lowered the price target from $20 to $3.75.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 4:30 pm

U.S. stocks traded higher with the S&P 500 gaining 1.5%. Alibaba reported weak revenue, missing analyst estimates. Cingulate, AST SpaceMobile, and Gambling.com saw significant stock price increases, while Turnstone Biologics, SIGA Technologies, and Terran Orbital experienced sharp declines.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 6:23 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 2%. Walmart reported strong Q2 results and raised full-year guidance. Cingulate, AST SpaceMobile, and SciSparc saw significant stock price increases, while Turnstone Biologics, SIGA Technologies, and Terran Orbital experienced sharp declines.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 4:27 pm

Turnstone Biologics Corp. (NASDAQ:TSBX) released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC). The data showed a 25% overall response rate and a 50% disease control rate among four evaluable patients. The company is now focusing on high unmet medical need cancers, including colorectal cancer, head and neck cancer, and uveal melanoma. Despite the promising data, TSBX stock is down 57.53% to 93 cents.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 3:57 pm

U.S. stocks surged with the Dow Jones gaining over 500 points, driven by a 1% rise in U.S. retail sales for July. Consumer discretionary shares led the gains, while utilities lagged. Notable stock movements included significant gains for Cingulate Inc., VS MEDIA Holdings Limited, and SciSparc Ltd., and sharp declines for Turnstone Biologics Corp., SIGA Technologies, Inc., and Terran Orbital Corporation.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 1:46 pm

Turnstone Biologics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:22 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.